Alexander Spira, WCLC 2021: PERLA: Randomized Phase II Trial of Dostarlimab + Chemotherapy vs Pembrolizumab + Chemotherapy in Metastatic Non-Squamous Non-small Cell Lung Cancer
touchONCOLOGY joins Dr Alexander Spira (Virginia Cancer Specialists, Fairfax, VA, USA) at WCLC 2021 to discuss the current, ongoing PERLA phase II clinical trial, that explores the efficacy of dostarlimab + chemotherapy versus pembrolizumab + chemotherapy in metastatic non-squamous non-small cell lung cancer.
ClinicalTrials.gov Identifier: NCT04581824Â
Questions
1. What are the potential advantages of dostarlimab in the treatment of patients with NSCLC? (00:11-01:05)
2. What are the aims and design of the PERLA study? (01:05-01:39)
3. What are the inclusion and exclusion criteria of the study? (01:39-02:05)
4. When are data expected? (02:05-02:32)
Disclosures: Alexander Spira discloses Leadership involvement with NEXT Oncology Virginia; Stock and Other Ownership Interests from Eli Lilly; Honoraria from CytomX Therapeutics, AstraZeneca/MedImmune, Merck, Takeda, Amgen, Janssen Oncology, Novartis, Bristol-Myers Squibb and Bayer; Consulting or Advisory Roles from Incyte, Amgen, Novartis, Mirati Therapeutics, Gritstone Oncology, Jazz Pharmaceuticals, Takeda, Janssen Research & Development, Array BioPharma, AstraZeneca/MedImmune, AstraZeneca/MedImmune, Merck, Bristol-Myers Squibb; Research Funding for his Institution from LAM Therapeutics, Roche, AstraZeneca; Boehringer Ingelheim, Astellas Pharma, MedImmune, Novartis, Newlink Genetics, Incyte, Abbvie, Ignyta, LAM Therapeutics, Trovagene, Takeda, Macrogenics, CytomX Therapeutics, Astex Pharmaceuticals, Bristol-Myers Squibb, Loxo, Arch Therapeutics, Gritstone, Plexxikon, Amgen, Loxo, Daiichi Sankyo, ADCT, Janssen Oncology, Mirati Therapeutics, ADCT and Rubius.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson.
Filmed in coverage of the 2021 WCLC Annual Meeting.
